Elevation and persistence of CD8 T-cells in HIV infection: The Achilles heel in the ART era

Journal of the International AIDS Society

Volumn 19, Issue 1, 2016, Pages

  Cao, Wei ^a,b   Mehraj, Vikram ^a   Kaufmann, Daniel E ^c,d   Li, Taisheng ^b   Routy, Jean Pierre ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antiretroviral therapy; Bystander activation; CD8 T cell persistence; HIV; T cell exhaustion

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOKINE;

AGING; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL MIGRATION; CELLULAR DISTRIBUTION; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSENESCENCE; LONG TERM CARE; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; FEMALE; HIV INFECTIONS; IMMUNOLOGY;

ANTI-HIV AGENTS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS;

EID: 84960154698     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.19.1.20697     Document Type: Article

References (92)

1. Helleberg M, Kronborg G, Ullum H, Ryder LP, Obel N, Gerstoft J. Course and clinical significance of CD8+ T-cell counts in a large cohort of HIV-infected individuals. J Infect Dis. 2015; 211(11): 1726-34.
2. Emu B, Moretto WJ, Hoh R, Krone M, Martin JN, Nixon DF, et al. Composition and function of T cell subpopulations are slow to change despite effective antiretroviral treatment of HIV disease. PLoS One. 2014; 9(1): 85613.
3. Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIVinfected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014; 10(5): 1004078.
4. Parry H, Cohen S, Schlarb JE, Tyrrell DA, Fisher A, Russell MA, et al. Smoking, alcohol consumption, and leukocyte counts. Am J Clin Pathol. 1997; 107(1): 64-7.
5. Garcia-Dabrio MC, Pujol-Moix N, Martinez-Perez A, Fontcuberta J, Souto JC, Soria JM, et al. Influence of age, gender and lifestyle in lymphocyte subsets: Report from the Spanish Gait-2 Study. Acta Haematol. 2012; 127(4): 244-9.
6. Freeman ML, Mudd JC, Shive CL, Younes SA, Panigrahi S, Sieg SF, et al. CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-Treated HIV Infection. Clin Infect Dis. 2016; 62(3): 392-6.
7. Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Ferguson FG. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: The Swedish longitudinal OCTO immune study. Mech Age Dev. 2000; 121(1-3): 187-201.
8. Wikby A, Johansson B, Olsson J, Lofgren S, Nilsson BO, Ferguson F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: The Swedish NONA immune study. Exp Gerontol. 2002; 37(2-3): 445-53.
9. Ferguson FG, Wikby A, Maxson P, Olsson J, Johansson B. Immune parameters in a longitudinal study of a very old population of Swedish people: A comparison between survivors and nonsurvivors. J Gerontol A Biol Sci Med Sci. 1995; 50(6): B378-82.
10. Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Lofgre S, et al. An immune risk phenotype, cognitive impairment, and survival in very late life: Impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci. 2005; 60(5): 556-65.
11. Strindhall J, Skog M, Ernerudh J, Bengner M, Lofgren S, Matussek A, et al. The inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: The Swedish HEXA immune study. Age (Dordr). 2013; 35(3): 985-91.
12. Boren E, Gershwin ME. Inflamm-Aging: Autoimmunity, and the immunerisk phenotype. Autoimmun Rev. 2004; 3(5): 401-6.
13. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011; 62: 141-55.
14. Ndumbi P, Gilbert L, Tsoukas CM. Comprehensive evaluation of the immune risk phenotype in successfully treated HIV-infected individuals. PLoS One. 2015; 10(2): 0117039.
15. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med. 2009; 206(6): 1253-72.
16. Streeck H, Lu R, Beckwith N, Milazzo M, Liu M, Routy JP, et al. Emergence of individual HIV-specific CD8 T cell responses during primary HIV-1 infection can determine long-Term disease outcome. J Virol. 2014; 88(21): 12793-801.
17. Lewis MG, DaFonseca S, Chomont N, Palamara AT, Tardugno M, Mai A, et al. Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS. 2011; 25(11): 1347-56.
18. Ananworanich J, Vandergeeten C, Chomchey N, Phanuphak N, Ngauy V, Sekaly R-P, et al. Early ART Intervention restricts the seeding of the HIV reservoir in long-lived central memory CD4 T cells. Abstract #47. In: Conference on Retroviruses and Opportunistic Infections; 2013 Mar 3-6; Atlanta, GA. 2013.
19. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA, Herzenberg LA. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest. 1995; 95(5): 2061-6.
20. Cao W, Jamieson BD, Hultin LE, Hultin PM, Effros RB, Detels R. Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr. 2009; 50(2): 137-47.
21. Ronsholt FF, Ullum H, Katzenstein TL, Gerstoft J, Ostrowski SR. T-cell subset distribution in HIV-1-infected patients after 12 years of treatment-induced viremic suppression. J Acquir Immune Defic Syndr. 2012; 61(3): 270-8.
22. Cao W, Mehraj V, Trottier B, Baril JG, Leblanc R, Lebouche B, et al. Early initiation rather than prolonged duration of antiretroviral therapy in HIV infection contributes to the normalization of CD8 T-cell counts. Clin Infect Dis. 2016; 62(2): 250-7.
23. Lu W, Mehraj V, Vyboh K, Cao W, Pexos C, Routy JP. Normalization of CD4/CD8 ratio after long-Term antiretroviral therapy: Gender and aging issues. Abstract O064. In: The 24th Annual Canadian Conference on HIV/AIDS Research; 2015 Apr 30-May 3; Toronto, ON, Canada; 2015.
24. Vrisekoop N, Drylewicz J, Van Gent R, Mugwagwa T, Van Lelyveld S, Veel E, et al. Quantification of naive and memory T-cell turnover during HIV-1 infection. AIDS. 2015; 29(16): 2071-80.
25. Tinago W, Coghlan E, Macken A, McAndrews J, Doak B, Prior-Fuller C, et al. Clinical, immunological and treatment-related factors associated with normalised CD4+/CD8+T-cell ratio: Effect of naive and memory T-cell subsets. PLoS One. 2014; 9(5): E97011.
26. Jenabian MA, El-Far M, Vyboh K, Kema I, Kema I, Costiniuk CT, Thomas R, et al. Immunosuppressive tryptophan catabolism and gut mucosal dysfunction following early HIV infection. J Infect Dis. 2015; 212(3): 355-66.
27. Tedla N, Dwyer J, Truskett P, Taub D, Wakefield D, Lloyd A. Phenotypic and functional characterization of lymphocytes derived from normal and HIV-1-infected human lymph nodes. Clin Exp Immunol. 1999; 117(1): 92-9.
28. Biancotto A, Grivel JC, Iglehart SJ, Vanpouille C, Lisco A, Sieg SF, et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood. 2007; 109(10): 4272-9.
29. Allers K, Puyskens A, Epple HJ, Schurmann D, Hofmann J, Moos V, et al. The effect of timing of antiretroviral therapy on CD4 T-cell reconstitution in the intestine of HIV-infected patients. Mucosal Immunol. 2016; 9(1): 265-74.
30. Serrano-Villar S, Perez-Elias MJ, Dronda F, Casado JL, Moreno A, Royuela A, et al. Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio. PLoS One. 2014; 9(1): E85798.
31. Leon A, Leal L, Torres B, Lucero C, Inciarte A, Arnedo M, et al. Association of microbial translocation biomarkers with clinical outcome in controllers HIVinfected patients. AIDS. 2015; 29(6): 675-81.
32. Gupta SK, Kitch D, Tierney C, Melbourne K, Ha B, McComsey GA. Markers of renal disease and function are associated with systemic inflammation in HIV infection. HIV Med. 2015; 16(10): 591-8.
33. Betene ADC, De Wit S, Neuhaus J, Palfreeman A, Pepe R, Pankow JS, et al. Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy. J Acquir Immune Defic Syndr. 2014; 67(5): 538-46.
34. Doisne JM, Urrutia A, Lacabaratz-Porret C, Goujard C, Meyer L, Chaix ML, et al. CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol. 2004; 173(4): 2410-8.
35. Wilson JD, Ogg GS, Allen RL, Davis C, Shaunak S, Downie J, et al. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS. 2000; 14(3): 225-33.
36. Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, Brenchley JM, Casazza JP, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: Relationship to viral load in untreated HIV infection. J Virol. 2001; 75(24): 11983-91.
37. Ogg GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, Monard S, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol. 1999; 73(1): 797-800.
38. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science. 1996; 272(5270): 1947-50.
39. Kim SK, Brehm MA, Welsh RM, Selin LK. Dynamics of memory T cell proliferation under conditions of heterologous immunity and bystander stimulation. J Immunol. 2002; 169(1): 90-8.
40. Bastidas S, Graw F, Smith MZ, Kuster H, Gunthard HF, Oxenius A. CD8+ T cells are activated in an antigen-independent manner in HIV-infected individuals. J Immunol. 2014; 192(4): 1732-44.
41. McNally JM, Zarozinski CC, Lin MY, Brehm MA, Chen HD, Welsh RM. Attrition of bystander CD8 T cells during virus-induced T-cell and interferon responses. J Virol. 2001; 75(13): 5965-76.
42. Vezys V, Yates A, Casey KA, Lanier G, Ahmed R, Antia R, et al. Memory CD8 T-cell compartment grows in size with immunological experience. Nature. 2009; 457(7226): 196-9.
43. Chirullo B, Sgarbanti R, Limongi D, Shytaj IL, Alvarez D, Das B, et al. A candidate anti-HIV reservoir compound, auranofin, exerts a selective 'antimemory' effect by exploiting the baseline oxidative status of lymphocytes. Cell Death Dis. 2013; 4: E944.
44. Eggena MP, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C, et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol. 2005; 174(7): 4407-14.
45. Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, Daucher M, et al. CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med. 2004; 200(3): 331-43.
46. Jenabian MA, Patel M, Kema I, Kanagaratham C, Radzioch D, Thebault P, et al. Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers. PLoS One. 2013; 8(10): 78146.
47. Seddiki N, Kaufmann DE. Editorial overview: Cell dysfunction and exhaustion in HIV infection. Curr Opin HIV AIDS. 2014; 9(5): 437-8.
48. Radebe M, Gounder K, Mokgoro M, Ndhlovu ZM, Mncube Z, Mkhize L, et al. Broad and persistent Gag-specific CD8+ T-cell responses are associated with viral control but rarely drive viral escape during primary HIV-1 infection. AIDS. 2015; 29(1): 23-33.
49. Peretz Y, He Z, Shi Y, Yassine-Diab B, Goulet JP, Bordi R, et al. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog. 2012; 8(8): 1002840.
50. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood. 2003; 101(7): 2711-20.
51. Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep. 2010; 7(1): 4-10.
52. Youngblood B, Noto A, Porichis F, Akondy RS, Ndhlovu ZM, Austin JW, et al. Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. J Immunol. 2013; 191(2): 540-4.
53. Youngblood B, Hale JS, Ahmed R. Memory CD8 T cell transcriptional plasticity. F1000Prime Rep. 2015; 7: 38.
54. Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science. 2009; 324(5934): 1569-72.
55. Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science. 2009; 324(5934): 1572-6.
56. Iannello A, Boulassel MR, Samarani S, Debbeche O, Tremblay C, Toma E, et al. Dynamics and consequences of IL-21 production in HIV-infected individuals: A longitudinal and cross-sectional study. J Immunol. 2010; 184(1): 114-26.
57. Chevalier MF, Julg B, Pyo A, Flanders M, Ranasinghe S, Soghoian DZ, et al. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol. 2011; 85(2): 733-41.
58. Zoon CK, Wan W, Graham L, Bear HD. Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma. Int J Mol Sci. 2015; 16(4): 8744-60.
59. Vigano S, Negron J, Ouyang Z, Rosenberg ES, Walker BD, Lichterfeld M, et al. Prolonged antiretroviral therapy preserves HIV-1-specific CD8 T cells with stem cell-like properties. J Virol. 2015; 89(15): 7829-40.
60. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015; 15(8): 486-99.
61. Farber DL, Yudanin NA, Restifo NP. Human memory T cells: Generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014; 14(1): 24-35.
62. Kalayjian RC, Landay A, Pollard RB, Taub DD, Gross BH, Francis IR, et al. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: Association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis. 2003; 187(12): 1924-33.
63. Le Priol Y, Puthier D, Lecureuil C, Combadiere C, Debre P, Nguyen C, et al. High cytotoxic and specific migratory potencies of senescent CD8+ CD57+ cells in HIV-infected and uninfected individuals. J Immunol. 2006; 177(8): 5145-54.
64. Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, et al. Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol. 2004; 2(2): E20.
65. Kim J, Kim AR, Shin EC. Cytomegalovirus infection and memory T cell inflation. Immune Netw. 2015; 15(4): 186-90.
66. Derhovanessian E, Larbi A, Pawelec G. Biomarkers of human immunosenescence: Impact of Cytomegalovirus infection. Curr Opin Immunol. 2009; 21(4): 440-5.
67. Lee SA, Sinclair E, Hatano H, Hsue PY, Epling L, Hecht FM, et al. Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging. PLoS One. 2014; 9(2): 89444.
68. Lee SA, Sinclair E, Jain V, Huang Y, Epling L, Van Natta M, et al. Low proportions of CD28-CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. J Infect Dis. 2014; 210(3): 374-82.
69. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002; 8(4): 379-85.
70. Catalfamo M, Di Mascio M, Hu Z, Srinivasula S, Thaker V, Adelsberger J, et al. HIV infection-Associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci USA. 2008; 105(50): 19851-6.
71. Catalfamo M, Wilhelm C, Tcheung L, Proschan M, Friesen T, Park JH, et al. CD4 and CD8 T cell immune activation during chronic HIV infection: Roles of homeostasis, HIV, type I IFN, and IL-7. J Immunol. 2011; 186(4): 2106-16.
72. Lehmann C, Jung N, Forster K, Koch N, Leifeld L, Fischer J, et al. Longitudinal analysis of distribution and function of plasmacytoid dendritic cells in peripheral blood and gut mucosa of HIV infected patients. J Infect Dis. 2014; 209(6): 940-9.
73. Routy JP, Mehraj V, Vyboh K, Cao W, Kema I, Jenabian MA. Clinical relevance of kynurenine pathway in HIV/AIDS: An immune checkpoint at the crossroads of metabolism and inflammation. AIDS Rev. 2015; 17(2): 96-106.
74. Kamath AT, Sheasby CE, Tough DF. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-Alpha beta and IFN-gamma. J Immunol. 2005; 174(2): 767-76.
75. Lugli E, Mueller YM, Lewis MG, Villinger F, Katsikis PD, Roederer M. IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques. Blood. 2011; 118(9): 2520-9.
76. Shive CL, Mudd JC, Funderburg NT, Sieg SF, Kyi B, Bazdar DA, et al. Inflammatory cytokines drive CD4+T-cell cycling and impaired responsiveness to interleukin 7: Implications for immune failure in HIV disease. J Infect Dis. 2014; 210(4): 619-29.
77. Laidlaw BJ, Cui W, Amezquita RA, Gray SM, Guan T, Lu Y, et al. Production of IL-10 by CD4(+) regulatory T cells during the resolution of infection promotes the maturation of memory CD8(+) T cells. Nat Immunol. 2015; 16(8): 871-9.
78. Vignali DA, Collison LW,Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008; 8(7): 523-32.
79. Wilson EM, Singh A, Hullsiek KH, Gibson D, Henry WK, Lichtenstein K, et al. Monocyte-Activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. J Infect Dis. 2014; 210(9): 1396-406.
80. Hubert A, Subra C, Jenabian MA, Tremblay Labrecque PF, Tremblay C, Laffont B, et al. Elevated abundance, size and microRNA content of plasma extracellular vesicles in viremic HIV-1+ patients: Correlations with known markers of disease progression. J Acquir Immune Defic Syndr. 2015; 70(3): 219-27.
81. Kenway-Lynch CS, Das A, Lackner AA, Pahar B. Cytokine/Chemokine responses in activated CD4+ and CD8+ T cells isolated from peripheral blood, bone marrow, and axillary lymph nodes during acute simian immunodeficiency virus infection. J Virol. 2014; 88(16): 9442-57.
82. Shacklett BL, Cox CA, Quigley MF, Kreis C, Stollman NH, Jacobson MA, et al. Abundant expression of granzyme A, but not perforin, in granules of CD8+ T cells in GALT: Implications for immune control of HIV-1 infection. J Immunol. 2004; 173(1): 641-8.
83. Zaegel-Faucher O, Bregigeon S, Cano CE, Obry-Roguet V, Nicolino-Brunet C, Tamalet C, et al. Impact of hepatitis C virus coinfection on T-cell dynamics in long-Term HIV-suppressors under combined antiretroviral therapy. AIDS. 2015; 29(12): 1505-10.
84. Zheng L, Taiwo B, Gandhi RT, Hunt PW, Collier AC, Flexner C, et al. Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-Term antiretroviral therapy. J Acquir Immune Defic Syndr. 2014; 67(2): 153-60.
85. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006; 12(10): 1198-202.
86. Kepp O, Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, et al. Anticancer activity of cardiac glycosides: At the frontier between cell-Autonomous and immunological effects. Oncoimmunology. 2012; 1(9): 1640-2.
87. Jones RB,Walker BD. HIV-specific CD8+ T cells and HIV eradication. J Clin Invest. 2016; 126(2): 455-63.
88. Zarogoulidis P, Lampaki S, Yarmus L, Kioumis I, Pitsiou G, Katsikogiannis N, et al. Interleukin-7 and interleukin-15 for cancer. J Cancer. 2014; 5(9): 765-73.
89. Rhode PR, Egan JO, Xu W, Hong H,Webb GM, Chen X, et al. Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol Res. 2016; 4(1): 49-60.
90. Fukazawa Y, Lum R, Okoye AA, Park H, Matsuda K, Bae JY, et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med. 2015; 21(2): 132-9.
91. Sabahi R, Anolik JH. B-cell-Targeted therapy for systemic lupus erythematosus. Drugs. 2006; 66(15): 1933-48.
92. Margolis DM, Salzwedel K, Chomont N, Psomas C, Routy J, Poli G, et al. Highlights from the Seventh International Workshop on HIV Persistence during Therapy, 8-11 December 2015, Miami, Florida, USA. J Virus Erad. 2015; 2(1): 57-65.